Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg

International Journal of Cancer

Volumn 125, Issue 1, 2009, Pages 115-123

  Bauer, Stefan ^a,g   Oosterwijk Wakka, Jeannette C ^b   Adrian, Nicole ^c   Oosterwijk, Egbert ^b   Fischer, Eliane ^a   Wüest, Thomas ^a   Stenner, Frank ^a   Perani, Angelo ^d   Cohen, Leonard ^e   Knuth, Alexander ^a   Divgi, Chaitanya ^f   Jäger, Dirk ^g   Scott, Andrew M ^d   Ritter, Gerd ^e   Old, Lloyd J ^e   Renner, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAARLAND UNIVERSITY   (Germany)

^d AUSTIN HOSPITAL   (Australia)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cytokines; Recombinant antibody; Renal cell cancer; Tumor targeting

Indexed keywords

CARBONATE DEHYDRATASE IX; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; IODINE 125; IODINE 131; RECOMBINANT TUMOR NECROSIS FACTOR; CANCER VACCINE; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; RADIOACTIVE IODINE; RECOMBINANT GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG UPTAKE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; XENOGRAFT; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; IMMUNOLOGY; KIDNEY TUMOR; METABOLISM; MONONUCLEAR CELL; NUDE MOUSE; PATHOLOGY; TISSUE DISTRIBUTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CELLS, CULTURED; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA, RECOMBINANT; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, NUDE; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149113671     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24359     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Levi F, Lucchini F, Negri E, La Vecchia C. Declining mortality from kidney cancer in Europe. Ann Oncol 2004;15:1130-5.
3. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-8.
4. Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, Patard JJ. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008;54:315-25.
5. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
6. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741-6.
7. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529-37.
8. Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5:s3268-s74.
9. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 2007;7:13.
10. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007;8:304-10.
11. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Voller MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006;175:57-62.
12. Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007;7:14.
13. Bauer S, Adrian N, Williamson B, Panousis C, Fadle N, Smerd J, Fettah I, Scott AM, Pfreundschuh M, Renner C. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol 2004;172:3930-9.
14. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
15. Creasey AA, Reynolds MT, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986;46:5687-90.
16. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56.
17. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008;13:507-18.
18. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
19. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
20. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996;93:13791-6.
21. Schreiber RD, Hicks LJ, Celada A, Buchmeier NA, Gray PW. Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol 1985;134:1609-18.
22. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.
23. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
24. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
25. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983;80:5397-401.
26. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986;46:3990-3.
27. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14.
28. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, III, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988;6:344-50.
29. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5.
30. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32.
31. Eggermont AM, ten Hagen TL. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001;3:359-67.
32. Lejeune FJ, Kroon BB, Di Filippo F, Hoekstra HJ, Santinami M, Lienard D, Eggermont AM. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001;10:821-32, ix.
33. Bauer S, Adrian N, Fischer E, Kleber S, Stenner F, Wadle A, Fadle N, Zoellner A, Bernhardt R, Knuth A, Old LJ, Renner C. Structure-activity profiles of Ab-derived TNF fusion proteins. J Immunol 2006;177:2423-30.
34. Espevik T, Nissen-Meyer J. A highly sensitive cell line. WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986;95:99-105.
35. Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H, Lee MS. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective. NF-kappa. B through. STAT1/IRF-1 pathways. J Biol Chem 2001;276:13153-9.
36. Steffens MG, Boerman OC, Oyen WJ, Kniest PH, Witjes JA, Oosterhof GO, van Leenders GJ, Debruyne FM, Corstens FH, Oosterwijk E. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999;59:1615-19.
37. Yilmaz A, Bieler G, Spertini O, Lejeune FJ, Ruegg C. Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. Int J Cancer 1998;77:592-9.
38. van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, Oyen WJ, Corstens FH, Boerman OC. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med 2005;46:495-501.
39. Thiry A, Dogne JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566-73.
40. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SW. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990;31:1501-9.
41. Shaw SK, Perkins BN, Lim YC, Liu Y, Nusrat A, Schnell FJ, Parkos CA, Luscinskas FW. Reduced expression of junctional adhesion molecule and platelet/endothelial cell adhesion molecule-1 (CD31) at human vascular endothelial junctions by cytokines tumor necrosis factor-alpha plus interferon-gamma does not reduce leukocyte transmigration under flow. Am J Pathol 2001;159:2281-91.
42. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, Schmitz P, Clarke J, Steinmann G, Rosenkaimer F, Lejeune FJ. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.
43. Furrer M, Altermatt HJ, Ris HB, Althaus U, Ruegg C, Lienard D, Lejeune FJ. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res 1997;7(Suppl 2):S43-S49.
44. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 2004;64:7150-5.
45. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 2005;65:2906-13.
46. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002;110:475-82.
47. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-40.
48. Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM, Wiltrout RH. IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000;164:231-9.
49. Red-Horse K, Ferrara N. Imaging tumor angiogenesis. J Clin Invest 2006;116:2585-7.
50. Aulitzky WE, Aulitzky WK, Frick J, Herold M, Gastl G, Tilg H, Berger M, Huber C. Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. Immunobiology 1990;180:385-94.
51. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007;67:1257-64.